ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
Drug companies play a key role in improving cancer care, but financial toxicity for patients continues to worsen. Eternal vigilance is the price of liberty from excessive drug costs, and we have an ethical obligation to hold pharmaceutical companies accountable.
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
How we report clinical trials makes interpreting their results harder. Why shouldn’t we all have more information to make better decisions for our patients?
Deciding whether RNI works depends upon not only accurate risk assessment but also a better understanding of the disease. Here are some key elements of breast cancer and treatment that aren’t adequately decided just by looking at pathologic stage, grade, and surgery type.
To determine when radiation helps treat lymph nodes, we need to carefully interpret surgical findings and accurately stage breast cancer to best understand the risk of lymph node involvement.
Two recently published large clinical trials, NCIC MA.20 and EORTC 22922, raised a lot of interest in and a lot of questions about when radiation helps for treating lymph nodes in breast cancer. The data are more complicated than often presented.
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
ASCO CEO Dr. Allen S. Lichter reflects on an optimistic approach to the challenges of providing high-quality cancer care around the globe on World Cancer Day.
Prevention is better than cure—an age-old saying, but one that is highly relevant in these times of increasing incidence of diseases and skyrocketing health care costs, notes Dr. Monica Malik.
One of the most frequent questions I hear in my clinic is, “Are we making any progress?” or, “Is there anything new out there?” The answer is always yes, or more properly, YES!
The past year had been a tremendously exciting time to be an oncologist, and to be a lung cancer oncologist in particular. It seems we hardly have time to get used to one newly approved agent before another one becomes available.
Peer reviewers are assumed to appear fully formed, like Athena springing from Zeus’ forehead, and usually they are not required to undergo any sort of orientation. We aim to change that, in our small way, by creating the JGO Editorial Fellowship.
I think the facet of cancer most commonly misunderstood by non-scientists (patients/families) is heterogeneity. Several presentations at the Prostate Cancer Foundation Annual Retreat touched on this theme.
The good kind of problem is having too many choices; the bad kind of problem is having too few choices. Today, I am writing about the ultimate in the good kind of problems: Being an exceptional responder to cancer treatment. I am even trying to enroll in the NCI Exceptional Responders Initiative.
This year’s Community Research Forum Annual Meeting is right around the corner. As Chair of the CRF Council, I am very excited about the Meeting and would like to invite you to participate in this unique opportunity.
Looking back on the 1976 Bonadonna study using CMF chemotherapy in women with breast cancer and positive axillary nodes, I consider what went wrong in the search for similarly effective treatment of prostate cancer.
Blogs
ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
No Results.
Pages
Advertisement